spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

PCI Welcomes Al Moss as Philadelphia General Manager


Philadelphia, PA – September 26, 2017 – PCI Pharma Services (PCI) is pleased to announce that Al Moss has assumed the role of Vice President and General Manager of its Philadelphia, PA location. The site serves as PCI’s corporate headquarters as well as a Center of Excellence for contract packaging services for commercial medicines, medical devices and consumer healthcare products. PCI operates an extensive global supply network across North America and Europe, supporting medicines destined to over 100 countries worldwide.

Al comes to PCI with outstanding credentials and a proven record of results, holding progressive leadership positions at industry-leading companies including Procter and Gamble, General Mills, SABMiller, British Petroleum (BP) and most recently at Coty, Inc. where he led North American Skincare and Fragrance Operations. His track record of demonstrated success throughout his career spans virtually all elements of supply chain, including distribution and warehousing, logistics and transportation, supplier enablement, production, and customer capability development. In addition to his professional experience, Al holds a Bachelor’s degree in Industrial and Systems Engineering from North Carolina A&T State University, an MBA in Operations Management from the University of Iowa, and a Master’s Degree in Supply Chain Management from Penn State.

"We are very excited to have Al join the PCI team," stated Bill Mitchell, Chief Executive Officer. “Al brings a diverse background in supply chain and production and truly understands the needs of our customers. His personal commitment to customer satisfaction underscores the company's focus on true strategic partnership and providing the industry’s leading customer experience. Al's demonstrated leadership has him well positioned to lead the Philadelphia team."

The PCI Philadelphia facility recently expanded site capacity by adding additional high speed bottling and blister packaging lines, as well as a significant expansion of its Serialization capacity, part of a multi-site installation that will have PCI realize more than 80 lines of Serialization readiness. Other notable capital investments include the expansion of the site’s 2-8C Cold Chain storage, adding to the Cold Chain capabilities at the Rockford, IL and Bridgend, UK facilities. This is the latest in a series of significant investments by PCI to facilitate their strategic expansion of services, positioning PCI to best support trends in the pharmaceutical marketplace.

About PCI

The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over four decades in the healthcare business. Leading technology and continued investment enables us to address global development needs throughout the product life cycle — from Phase I clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit www.pciservices.com or follow us on Twitter at @PCI_Social.

Al Moss

 
Print this page
Send to a friend
   
spacer
News and Press Releases

Haselmeier Relies on DQIQOQ Qualified Testing Machines and Zwicks Materials Testing Laboratory

Haselmeier is a leader in the development and manufacture of innovative self injection devices. Numerous international pharmaceutical manufacturers are customers of this Swiss company. In addition to testing production batches of pen injectors, Zwick's Materials Testing Laboratory offers DQ/IQ/OQ qualification and measurement system analysis of the testing system used for the tests.
More info >>


White Papers

Accelerate Your Database Lock Using Clean Patient Optics

Bioclinica

Because a key step towards database lock is obtaining clean data for all patients, the ability to verify that data are clean early accelerates the ability to lock the clinical database. This ultimately shortens the overall study timeline while ensuring the quality of your data. However, this can be challenging when manually reviewing study data, particularly with larger studies.
More info >>

Industry Events

SAPHEX 2018

1-2 November 2018, Gallagher Convention Centre, Midrand, South Africa

The SAPHEX exhibition and conference is now established as the “go-to” networking and business event for anyone working in the South African pharmaceutical manufacturing industry.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement